April 16, 2018 9:40am
Closed down -$0.04 and is up +$0.0 or +7.28% to $1.09
ONVO continues to map out a range of relevant conditions for creating NASH, including all components of the disease (fat accumulation, inflammation and fibrosis).
ONVO has achieved several breakthrough capabilities for its 3D bioprinted tissues.
At last week’s International Liver CongressTM, two posters were presented illustrating ONVO’s ability to create functional human liver tissue, produce a spectrum of NASH disease conditions, and then treat that disease successfully with a client’s development stage non-alcoholic steatohepatitis (“NASH”) drug.
These posters highlighted the performance of Organovo’s human liver model in the generation of a robust non-alcoholic fatty liver disease (“NAFLD”) and NASH phenotype, including the presence of ‘gold standard’ histopathologic features.
Organovo and Merck & Co. (MRK) also jointly published a peer-reviewed study describing the Company’s bioprinted human intestinal model, which exhibits compelling architecture, barrier and metabolic functions, while also being able to model key aspects of toxicity and inflammation.